<code id='B9B3DB971D'></code><style id='B9B3DB971D'></style>
      • <acronym id='B9B3DB971D'></acronym>
      <center id='B9B3DB971D'><center id='B9B3DB971D'><tfoot id='B9B3DB971D'></tfoot></center><abbr id='B9B3DB971D'><dir id='B9B3DB971D'><tfoot id='B9B3DB971D'></tfoot><noframes id='B9B3DB971D'>
      • <optgroup id='B9B3DB971D'><strike id='B9B3DB971D'><sup id='B9B3DB971D'></sup></strike><code id='B9B3DB971D'></code></optgroup>
        5. <b id='B9B3DB971D'><label id='B9B3DB971D'><select id='B9B3DB971D'><dt id='B9B3DB971D'><span id='B9B3DB971D'></span></dt></select></label></b><u id='B9B3DB971D'></u>
          <i id='B9B3DB971D'><strike id='B9B3DB971D'><tt id='B9B3DB971D'><pre id='B9B3DB971D'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-09-30 07:07:34 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：7446
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          ALS advocates say criticism of new drugs misses bigger picture
                                
                            
          Next article：  
                                      
                                          After affirmative action ruling, medical educators look to 'holistic review'
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles